MDACC Study No:2012-1049 ( NCT No: NCT01841463)
Title:An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf«) or co-administration of P1446A-05 with Dabrafenib and Trametinib combination in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation
Principal Investigator:Adi Diab
Treatment Agent:P1446A-05; Vemurafenib
Study Status:Terminated
Study Description:The goal of this research study is to find the highest tolerable dose of
P1446A-05 that can be given with vemurafenib to patients with advanced
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I
Treatment Agents:P1446A-05
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Piramal Enterprises Limited
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Adi Diab
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults